Exact Sciences, Takeda Pharmaceuticals & more — 6 GI company key notes

Here are six updates on gastroenterology and endoscopy companies.

Dublin, Ireland-based Allergan entered a research, development, collaboration and license agreement to develop Indianapolis's Assembly Biosciences microbiome gastrointestinal development programs.

To combat its $30 billion debt, Lovell, Canada-based Valeant Pharmaceuticals is selling its Dendreon cancer business and three of its skincare brands for $2.12 billion.

Valeant Pharmaceuticals' board of directors elected Richard DeSchutter director.

Madison, Wis.-based Exact Sciences — the makers of Cologuard — anticipates revenue between $34.9 and $25.4 million for the fourth quarter of fiscal year 2016.

Blue Cross Blue Shield Association's Center for Clinical Effectiveness positively reviewed Madison, Wis.-based Exact Sciences' Cologuard, a fecal-based colonoscopy alternative.

Japan's Takeda Pharmaceuticals and San Diego's PvP Biologics are developing KumaMax, a novel enzyme that breaks down immune-reactive parts of gluten in the stomach, for patients with Celiac disease.

More articles on gastroenterology and endoscopy:
Dr. J. Calvin Coffey urges classification of new abdominal organ: 5 things to know
Cancer screening, but not colonoscopy, rates increase under ACA: 4 study insights
Which lifestyle factors are associated with serrated colorectal polyps? 5 study insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months